ArticleBMC pediatrics2026
Co-occurrence of low-grade fibromyxoid sarcoma and familial Tatton-Brown-Rahman syndrome with germline DNMT3A c.1904G > A (p.Arg635Gln): a case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTatton‑Brown‑Rahman syndrome (TBRS) is an ultra-rare overgrowth and neurodevelopmental disorder caused by germline DNMT3A variants. Neoplastic manifestations are rarely reported; consequently, data regarding tumor susceptibility in this condition remain limited. Low-grade fibromyxoid sarcoma (LGFMS) has not been previously reported in individuals with TBRS. CASE PRESENTATION: We report a 20‑year‑old male with clinical features of TBRS and a heterozygous germline DNMT3A NM_022552.5:c.1904G > A (p.Arg635Gln) variant, inherited from his father. The patient developed LGFMS at the age of 17 years. Histopathological and immunohistochemical findings supported the diagnosis. Molecular analysis confirmed the DNMT3A variant in blood and tumor tissue without loss of heterozygosity (LOH) by Sanger-based allelic comparison. Segregation analysis identified the variant in the affected father and sister, supporting pathogenicity and confirming familial transmission.
conclusionsThis case documents the first familial transmission of the DNMT3A c.1904G > A (p.Arg635Gln) variant in a Brazilian family, and describes the first reported co-occurrence of TBRS and LGFMS. While causality remains unproven, this finding suggests that germline disruption of epigenetic regulators may influence tumor susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.